Cargando…
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Androgen deprivation therapy remains the single most effective treatment for the initial therapy of advanced prostate cancer, but is uniformly marked by progression to castration-resistant prostate cancer (CRPC). Residual tumor androgens and androgen axis activation are now recognized to play a prom...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912049/ https://www.ncbi.nlm.nih.gov/pubmed/24501545 http://dx.doi.org/10.2147/CMAR.S39318 |